摘要
[目的]综合评估吡贝地尔与美多芭单独给药治疗早期帕金森病患者的预后效果。[方法]将本院收治的64例早期帕金森综合征患者作为研究对象，使用随机数字表法分为两组（r／=32），A组应用吡贝地尔治疗，B组应用关多芭治疗，治疗前后进行多巴胺转运体-单光子发射计算机断层成像（TRODAT-SPECT）检查，比较两组患者的99mTc-TRPDAT-1特异性摄取值、帕金森病量表（UPDRS）变化及临床疗效。[结果]治疗6个月和治疗10个月后，两组的UPDRS均显著降低，且A组治疗6个月、治疗10个月时的UPDRS评分均显著低于B组（P〈0．05）。A组患者受累肢体同侧及对侧的99mTc-TRODAT-1特异性摄取值降低百分率均显著低于B组（P〈0．05）。A组的治疗显效率、总有效率分别为40．63％、90．63％，均显著高于B组的25．。0％、65．62％（P〈0．05）。A组的不良反应发生率为18．75％，显著低于B组的31．25％（P〈0．05）。[结论]在早期帕金森综合征的临床治疗中，单独服用美多芭会加快多巴胺能神经元凋亡，促使病情恶化，而吡贝地尔不会对患者预后造成不良影响。
[Objective]To evaluate the comprehensive prognosis effect of piribedil and Madopar for the treatment of early Parkinson＇s syndrome when administered. [MethodsJSixty-four patients with early Parkin- son＇s syndrome in our hospital were selected as the research object. According to the random number table method, the patients were divided into two groups （ n =32）. Group A were treated with piribedil and Group B were treated with Madopar. Before and after treatment, 99mTc-TRPDAT-1 specific uptake value, UPDRS （Parkinson＇s disease） and clinical efficacy of patients in the two groups were tested and compared through do- pamine transporter-single photon emission computed tomography （TRODAT-SPECT）. [Results] At 6 months and 10 months after treatment, the UPDRS in the two groups were significantly reduced compared to before treatment. After 6 months and 10 months of treatment, the UPDRS scores in Group A were signifi- cantly lower than those in Group B （ P〈0.05）. The specific uptake values of 99mTc-TRODAT-1 on the ipsi- lateral and contralateral side of the patients in Group A were significantly lower than those in Group B （ P〈0.05）. The therapeutic effect rate and total effective rates in Group A were 40.63% and 90.63% respectively, which were significantly higher than 25.00% and 65.62% in Group 13 （ P 〈0.05）. The incidence of adverse re- actions in Group A was 18.75%, which was significantly lower than 31.25% in Group B （ P 〈0.05）. [Conclusion]In the clinical treatment of early Parkinson＇s syndrome, taking Madopar alone can accelerate the apoptosis of dopaminergic neurons and promote disease progression, while taking piribedil does not impact the prognosis of patients or cause adverse effects.
出处
《医学临床研究》
CAS
2016年第8期1477-1479,共3页
Journal of Clinical Research
